Advertisement
Home Tags Immunotherapy

Tag: Immunotherapy

Targeted Therapies Seem Beneficial for Immune Checkpoint Inhibitor-Related Myotoxicity

0

Myotoxicity-related fatality rate 3.4 percent after institution of screening coupled with active ventilation, treatment

PD-1 Inhibitor Treatment Effective for Localized Mismatch Repair-Deficient CRC

0

84.9 percent of 73 patients achieved objective response, including 23.3 percent with complete response

Oral Immunotherapy With Boiled Then Roasted Peanuts Feasible

0

Sequential approach is feasible and safe for peanut allergy, with very low frequency of rescue epinephrine use

QOL Up With Pembrolizumab Versus Ipilimumab, HDI in Resected Melanoma

0

Quality of life favored the pembrolizumab arm versus standard-of-care arm receiving ipilimumab, high-dose interferon α 2b

Treatment-Related Adverse Events of Antibody Drug Conjugates Identified

0

Overall incidence of treatment-related adverse events was 91.2 percent and included lymphopenia, nausea, neutropenia

Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma

0

Two-year overall survival higher for those initiating treatment with combo nivolumab/ipilimumab versus dual BRAF/MEK inhibition

Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC

0

Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse

Efficacy of Durvalumab for Early-Stage TNBC Examined by Race

0

In Phase I/II trial of durvalumab with neoadjuvant chemo, pathological complete response rates similar for Black, non-Black patients

The doctor shows the bladder of the person .

AUA: Immunotherapy Aids Survival in Muscle-Invasive Bladder Cancer

0

Patients receiving nivolumab had an approximately 30 percent lower likelihood of developing cancer recurrence versus placebo

Mental Health Issues Linked to Higher Risk of Breakthrough COVID Infections

Response to CAR-T Cell Therapy Similar for Minority Patients

0

Progression-free and overall survival similar for minority, nonminority patients receiving CAR-T cell therapy for non-Hodgkin lymphoma